A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia

A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia

Abstract Background Hepcidin plays a central role in iron homeostasis and erythropoiesis. Neutralizing hepcidin with a monoclonal antibody (mAb) may prevent ferroportin internalization, restore iron efflux from cells, and allow transferrin-mediated iron transport to the bone marrow. This multicenter...

Full description

Bibliographic Details
Main Authors: Saroj Vadhan-Raj, Rafat Abonour, Jonathan W. Goldman, David A. Smith, Christopher A. Slapak, Robert L. Ilaria, Ramon V. Tiu, Xuejing Wang, Sophie Callies, Joanne Cox, Jay L. Tuttle, Yiu-Keung Lau, Eric J. Roeland
Format: Article
Language:English
Published: BMC 2017-03-01
Series:Journal of Hematology & Oncology
Subjects:
Hepcidin
Ferritin
Iron
Cancer
Anemia
Online Access:http://link.springer.com/article/10.1186/s13045-017-0427-x

Internet

http://link.springer.com/article/10.1186/s13045-017-0427-x

Similar Items